Navigation Links
ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
Date:9/19/2011

CAMBRIDGE, Mass., Sept. 19, 2011 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) and Aestus Therapeutics, Inc., announced today the expansion of their current research collaboration agreement to test additional small-molecule compounds for the ability to slow or stop the progression of Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's disease).  The expanded scope of this collaboration is based on encouraging results from early-stage animal studies conducted in the past year under the existing collaboration.

(Logo: http://photos.prnewswire.com/prnh/20110204/DC42625LOGO)

"This collaboration is an important example of how our Institute, built by the ALS community -, is dedicated to speeding the development of new therapies and has become the leader in preclinical validation of potential treatments for ALS.  We are encouraged by these early results and look forward to expanding our partnership with Aestus on behalf of patients today," says Steve Perrin, Ph.D., president and CEO of ALS TDI.

The original research collaboration was established between ALS TDI and Aestus in March 2010 to test a compound identified by Aestus's proprietary gene-based drug discovery platform in an animal model of ALS. Results obtained by ALS TDI using their rigorous pre-clinical drug testing process were encouraging and warranted expansion of the collaboration to test compounds with a similar mode of action.  

"We at Aestus are delighted to expand our research collaboration with ALS TDI to identify novel therapeutics for this devastating disease," says Tage Honore, Ph.D. D.Sc., CEO and founder of Aestus.  "The expansion of our research agreement with ALS TDI is based on a truly collaborative approach involving scientists at both institutions. We are particularly gratified that the encouraging results from experiments at ALS TDI have helped to furt
'/>"/>

SOURCE ALS Therapy Development Foundation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Immune Deficiency Foundation Launches Free Accredited Course for Nurses About Primary Immunodeficiency and Immunoglobulin Therapy
2. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
3. Randomized Study Comparing Cell Therapeutics OPAXIO (Paclitaxel Poliglumex) and Radiotherapy to Standard of Care Temozolomide and Radiotherapy Treatment Open for Enrollment
4. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
5. Penn Receives $10 Million to Create Center for Orphan Disease Research and Therapy
6. Genethon and Childrens Hospital Boston Get FDA approval for a Wiskott Aldrich Gene Therapy Trial
7. RegenoCELL Announces That Patients Can Be Treated With Its Autologous Stem Cell Therapy in Greece
8. FDA Approves Dendreons Los Angeles Cancer Immunotherapy Manufacturing Facility
9. Celladon Corporation Announces Publication of Advanced Heart Failure Clinical Trial Results With MYDICAR® Enzyme Replacement Therapy in the Journal Circulation
10. Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy
11. Adeona Announces Positive Alzheimers Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Charm Sciences, Inc. is pleased ... (USDA), Grain Inspection, Packers and Stockyards Administration (GIPSA) ... Sciences to monitor aflatoxin in grains utilizing Charm’s ... FAST Aflatoxin Quantitative Test (solvent-based). , The Charm ... Water Extraction Technology to extract aflatoxin from the ...
(Date:5/21/2015)... May 21, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" ... company that develops and commercializes proprietary technologies and products ... operational results for the second fiscal quarter ended March ... Company continued to advance business with our existing customers ... , President and CEO of SQI. "The delivery of ...
(Date:5/21/2015)... , May 21, 2015  Susan Hedstrom, Executive ... a nonprofit organization dedicated to supporting research to ... (PWS), announced today that FPWR has received the ... Irina Shaulov contributed $1 million in support ... "Our gift ...
(Date:5/21/2015)...  The EveryLife Foundation for Rare Diseases applauded ... Amy Klobuchar (D-MN) today for introducing the ... or OPEN ACT. Supported by more ... bipartisan legislation promises to rapidly bring hundreds of ... patients by incentivizing drug makers to "repurpose" approved ...
Breaking Biology Technology:USDA-GIPSA (FGIS) Awards 5 Year Contract for Aflatoxin Tests to Charm Sciences 2SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8The Foundation for Prader-Willi Research Receives $1M Contribution in Support of Clinical Initiatives 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2
... , , ATLANTA, Sept. ... Board: EAUI), a leading provider of electrolyzed water for high-volume, ... trial with a leading international beverage bottling company enabling the ... sanitation process for CIP (Clean-in-Place) applications. EAU,s electrolyzed water ...
... , ... Expressionist modules Refiner Array and Analyst deliver expanded processing and reporting functionalities. ... Basel, ... leading provider of in silico solutions for pharmaceutical R&D and related life sciences, ...
... , , , CLEVELAND, ... GanedenBC30(R) , today announced the launch of the first ... the latest in a number of innovative probiotic-enhanced products introduced by Ganeden ... recent popularity of thin strips as a supplement delivery system led Ganeden ...
Cached Biology Technology:EAU Completes Approval Process for Electrolyzed Water as Sanitation Process for Industrial Clean-in-Place Application 2EAU Completes Approval Process for Electrolyzed Water as Sanitation Process for Industrial Clean-in-Place Application 3EAU Completes Approval Process for Electrolyzed Water as Sanitation Process for Industrial Clean-in-Place Application 4Genedata Expressionist with New Transcriptomics Biomarker Capabilities Advances Drug Development for Personalized Medicine 2Genedata Expressionist with New Transcriptomics Biomarker Capabilities Advances Drug Development for Personalized Medicine 3Genedata Expressionist with New Transcriptomics Biomarker Capabilities Advances Drug Development for Personalized Medicine 4Ganeden Biotech Introduces the First Probiotic Thin Strip 2Ganeden Biotech Introduces the First Probiotic Thin Strip 3
(Date:4/14/2015)...  HYPR Corp. today announced it has joined ... tm , an industry consortium transforming online authentication ... technology and collaborate to deliver open specifications for ... and private, and easier to use. ... sensitive user information and eliminates the dependency on ...
(Date:4/10/2015)... 10, 2015 Research and Markets ... "Security Competitive Profiles - NEC" report to ... NEC will continue to supply a range of ... with a company focus on the development of a ... Winning opportunities in the Asia-Pacific ...
(Date:4/2/2015)... , April 2, 2015 ... DERMALOG by far outperforms the strongest competitors, showing ... high accuracy, the system is capable of a ... speed proves up to be ten times faster ... its runner-up performance.      (Photo: ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... drugs currently studied in clinical trials appears to reduce ... at Georgetown University Medical Center report in an upcoming ... They say the results suggest that this class of ... been able to do-- prevent the long-term and continuing ...
... the specific biological mechanisms believed to lead to ... Diamond Blackfan anemia (DBA). Scientists say with further ... to current thinking about treatment for this disease ... George Thomas, PhD, Stefano Fumagalli, PhD, ...
... or ,gloopiness, of different parts of cancer cells increases ... according to new images that provide fundamental insights into ... today (15 March). The ... cells whilst they are dying as a result of ...
Cached Biology News:Alzheimer's disease therapeutic prevents long-term damage from TBI in pre-clinical studies 2Alzheimer's disease therapeutic prevents long-term damage from TBI in pre-clinical studies 3Cellular discovery may lead to targeted treatment for rare form of anemia 2Cellular discovery may lead to targeted treatment for rare form of anemia 3A sticky business -- how cancer cells become more 'gloopy' as they die 2
Anti-human CD48/BLAST-1, clone MEM102, Monoclonal Antibody...
Raf-1 (C-12)-G...
... DuoSet ELISA Development kit contains the basic ... ELISAs to measure natural and recombinant mouse ... and serum. Each kit contains sufficient materials ... plates, provided that the following conditions are ...
E1A (adenovirus early region 1)...
Biology Products: